AbstractBySubCategory

Prevention, Diagnosis, and Screening

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS). Simron Singh

224

Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo. Jordi Bruix

229

Impact of direct-acting antiviral agents-induced SVR on the long-term burden of hepatocellular carcinoma in chronic hepatitis C cirrhosis. Prowpanga Udompap

230

Multi-agent and single-agent chemotherapy in stage IV pancreatic cancer: An NCDB analysis. Aabra Ahmed

231

Short and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013. Talia Golan

232

Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma. Liping Huang

233

Larger size extracellular vesicle as early biomarker in patients with metastatic pancreatic cancer. Dong Uk Kim

234

HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets. Cecilia Grace Ethun

235

Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Alexandra G Lopez-Aguiar

236

Research on predictive value of five current staging systems in advanced hepatocellular carcinoma patients who received loco-regional therapies. Zhan-Hong Chen

237

Second cancer risk after diagnostic and monitoring radiation exposure with computed tomography in patients with hepatocellular carcinoma. Joong-Won Park

238

Early obesity and risk of cholangiocarcinoma in the United States. Akram Shalaby

239

Clinical features and tumor mutational profile of younger versus older patients with cholangiocarcinoma (CCA). Lipika Goyal

240

Application of ALBI and PALBI score as prognostic variables in hepatocellular carcinoma patients treated with transarterial-chemoembolization. Preetha Aravind

241

Real-world evidence (RWE) to show improved time to progression among resected pancreatic cancer (RPC) patients receiving adjuvant chemotherapy (adjch). Jonathan Kish

242

Incidentally discovered pancreatic ductal adenocarcinoma: Is detection of asymptomatic cancer associated with better outcomes than symptomatic cancer? Yoshinori Takeda

243

Multigene hereditary cancer panel testing for patients with pancreatic cancer. Anna K McGill

244

Comparison of the pathological features among HBV, HCV, and nonviral etiology-related hepatocellular carcinoma using explanted whole liver examinations. Hayato Akashi

245

A population-based study of biliary tract cancers (BTCs) in Alberta, Canada: How do our patients fare? Arthur Gregory Ang Lui

246

Health insurance and pancreatic cancer. Cameron Schlegel

247

Heterogeneous growth rates of pancreatic adenocarcinoma by retrospective analysis of CT imaging data. Tanner Mortenson

248

Role of HSF1 expression for tumor microenvironment in intrahepatic cholangiocarcinoma. Yu Saito

249

Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer. Tomohiro Kondo

250

Can we expect long-term survival in patients with extrahepatic metastasis of hepatocellular carcinoma? Kangpyo Kim

251

Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy. Masatoshi Kudo

252

Quantitative CT imaging features for hepatocellular carcinoma (HCC) with b-catenin (CTNNB1) gene mutation. Ahmed M. Khalaf

253

A population-based analysis of urban-rural disparities in advanced pancreatic cancer (APC) management and outcomes. Thomas Canale

254

Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Ysabel Ilagan-Ying

255

Tumor stage and primary treatment selection among a large cohort patients with hepatocellular carcinoma. Xue-Mei You

256

Comparision of adefovir and lamivudine for patients with hepatitis B virus-related hepatocellular carcinoma after hepatic resection. Xiao Xiang

257

Impact of preoperative sarcopenia and accelerated muscle loss on survival after resection of pancreatic cancer. Kyungjin Lee

258

Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma. Go Ninomiya

259

Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC). Angel Mier Hicks

260

Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer. Jaemin Jo

261

A study on thromboembolism of patients with pancreatic cancer. Kwan Yu LAM

262

Evaluation of tumor marker cancer antigen 72-4 (CA 72-4) in the monitoring of metastatic or recurrent tumors of the gastrointestinal tract, lung, breast, and ovaries. Anusiyanthan Isaac Mariampillai

263

Prognostic factors and scoring model for survival in advanced biliary tract cancer. Hyung Soon Park

264

Proposal of size-based surgical indication criteria for liver hemangioma based on a nationwide survey in Japan. Yoshihiro Sakamoto

265

A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. Caroline Elizabeth Poorman

266

Field deployable platform for prognostic hepatic cancer screening. Jill E. Shea

267

Visceral thromboses (VT) in pancreas adenocarcinoma (PDAC): A systematic review. Angel Mier Hicks

268

Ethnicity and hepatocellular carcinoma risk factors in New Mexico: A retrospective analysis over a 12-year period. Khine Zar Win

269

Cholangiocarcinomas: A study of patient and disease characteristics and the potential use of tumor molecular profiling. Petra Prins

270

The clinical impact of PET/CT with 68Ga-DOTATATE in neuroendocrine tumors (NETs): The experience of a private institution in Brazil. Jessica Sayuri Tsukamoto

271

Retrospective study of CT-guided radiofrequency ablation and laparoscopic radiofrequency ablation in the treatment of recurrent small hepatocellular carcinoma against the diaphragmatic dome. Qin Zheng

272

Agreement validation between axial imaging modalities and endoscopic ultrasonography in staging resectability of pancreatic cancer. Nghia Pham

273

Opportunities for improving outcomes in pancreatic cancer patients: Characterizing the unresected “resectable” population. Jonathan Kish

274

Prospective study of early detection of malignancies in individuals at risk for developing pancreatic cancer. Courtney Edwards Snyder

TPS500